Invivyd

IVVD on Nasdaq. Biological products, (no diagnostic substances). Market value $247m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Look carefully before going further

Read the warning sign in its own filings

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
-46.2%low

For every $100 of what the whole company costs, it produced $-46.16 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$0.81 a share, 53% above its 1-year low

Over the past year the price has ranged from $0.53 to $3.07.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

-0.2
-0.2
-0.2
-0.2
-0.1
-0.1
2021202220232024202512 monthsto Jun '26

Spare cash swings from quarter to quarter here: a shortfall of $110 million in the past 12 months, a shortfall of $58 million in the year to December 2025.

Revenue
n/an/a$0$25m$53m
Operating margin
n/an/an/a-696.8%-104.0%
Debt to equity
n/an/an/an/an/a
Shares outstanding
0.11bn0.11bn0.12bn0.23bn0.29bn

Health checks

  • Free cash flow positive0 of 5 years
  • Accounting checksSkipped: company is not yet profitable
  • DebtUnknown
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesNo, 170% more shares since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $14 million last quarter, up 21% on a year ago.
  • A loss of $44 million, compared with a loss of $15 million a year ago.
  • It loses 193 cents on each $1 of sales, compared with 246 cents a year earlier.
  • Over the past 12 months it spent $110 million more cash than it brought in, compared with $113 million a year earlier.
  • 167% more shares than a year ago. Each share owns a bit less of the company.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$9m
December 2024$14m
March 2025$11m
June 2025$12m
September 2025$13m
December 2025$17m
March 2026$14m
June 2026$14m
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024-$61m
December 2024-$18m
March 2025-$16m
June 2025-$15m
September 2025-$10m
December 2025-$11m
March 2026-$41m
June 2026-$44m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
5 March 2026
Next quarterly (estimated, 10-Q)
12 November 2026

Who owns it

None of the long-term investors we follow own it. 125 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

12 investors own more than 5%.

  • at least 12.1%+0.5 pts
    (filed with 1 related holder)
    Since 30 September 2025
  • BVF PARTNERS L P/IL
    Passive investor
    at least 10.0%+1.0 pts
    (filed with 9 related holders)
    Since 30 June 2026
  • Adimab, LLC
    Passive investor
    7.3%−1.5 pts
    Since 23 December 2025
  • at least 7.0%−2.9 pts
    (filed with 3 related holders)
    Since 31 March 2026
  • Maverick Capital, Ltd.
    Passive investor
    at least 6.7%−1.8 pts
    (filed with 2 related holders)
    Since 31 December 2025
  • Perceptive Advisors LLC
    Passive investor
    at least 6.3%−1.6 pts
    (filed with 2 related holders)
    Since 30 June 2026
  • BlackRock, Inc.
    Passive investor
    5.5%
    Since 30 June 2026
  • Mithril II GP LP
    Passive investor
    at least 4.8%
    (filed with 4 related holders)
    Since 22 August 2025
  • FMR LLC
    Passive investor
    at least 4.8%
    (filed with 1 related holder)
    Since 31 December 2024
  • Marc Elia
    Insider or founder
    at least 4.6%
    (filed with 1 related holder)
    Since 22 August 2025
  • Terrance McGuire
    Passive investor
    at least 3.0%
    (filed with 10 related holders)
    Since 22 August 2025
  • Soleus Capital Management, L.P.
    Passive investor
    at least 2.8%−2.3 pts
    (filed with 8 related holders)
    Since 31 December 2025
  • Sold down below 5%
    Since 31 March 2026
  • Deep Track Capital, LP
    Passive investor
    Sold down below 5%
    Since 30 September 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 1 insider bought $125,000 of shares on the open market. 5 sold $531,623, $531,623 of it under preset trading plans.

  • Lee Timothy Edward
    Chief Commercial Officer
    Sold
    under a preset trading plan
    Date
    18 August 2026
    Shares
    18,425
    Price
    $0.84
    Value
    $15,530
  • Green Julie
    Chief Human Resources Officer
    Sold
    under a preset trading plan
    Date
    18 August 2026
    Shares
    18,425
    Price
    $0.84
    Value
    $15,530
  • Duke William E.
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    18 August 2026
    Shares
    18,425
    Price
    $0.84
    Value
    $15,530
  • Andersen Jill
    Chief Legal Officer, Secretary
    Sold
    under a preset trading plan
    Date
    18 August 2026
    Shares
    30,706
    Price
    $0.84
    Value
    $25,882
  • Allen Robert D. III
    Chief Scientific Officer
    Sold
    under a preset trading plan
    Date
    18 August 2026
    Shares
    17,043
    Price
    $0.84
    Value
    $14,366
  • Lee Timothy Edward
    Chief Commercial Officer
    Sold
    under a preset trading plan
    Date
    17 August 2026
    Shares
    22,355
    Price
    $0.72
    Value
    $16,140
  • Green Julie
    Chief Human Resources Officer
    Sold
    under a preset trading plan
    Date
    17 August 2026
    Shares
    22,355
    Price
    $0.72
    Value
    $16,140
  • Duke William E.
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    17 August 2026
    Shares
    22,355
    Price
    $0.72
    Value
    $16,140
  • Andersen Jill
    Chief Legal Officer, Secretary
    Sold
    under a preset trading plan
    Date
    17 August 2026
    Shares
    37,256
    Price
    $0.72
    Value
    $26,899
  • Allen Robert D. III
    Chief Scientific Officer
    Sold
    under a preset trading plan
    Date
    17 August 2026
    Shares
    20,679
    Price
    $0.72
    Value
    $14,930

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in Invivyd’s filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 5 Mar 2026, plus the 10-Q filed 13 Aug 2026 and 8 later 8-Ks.

  • Doubt it can keep going

    Serious

    The company or its auditor warned it may not have enough money to last the next year.

    “Based on current operating plans and excluding future external financing, the Company will not have sufficient cash and cash equivalents to fund its operating expenses and capital requirements beyond one year from the issuance of these condensed consolidated financial statements, and therefore, the Company has concluded that there is substantial doubt about its ability to continue as a going concern.”

    From the 10-Q filed 13 August 2026, Part I, Item 1. Financial Statements. Read it in the filing

  • One big customer

    Worth knowing

    One customer brings in a big share of sales: 46% last year. Losing that customer would hurt.

    “Three specialty distributors accounted for 46%, 23% and 17% of total gross sales for the year ended December 31, 2025.”

    From the 10-K filed 5 March 2026, Item 1. Business. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.